Innovent Biologics (688428/09969) announced on July 15 details regarding the vesting outcomes of its 2023 STAR Market restricted stock incentive plan. The second vesting period for initially granted shares and the first vesting period for reserved shares will result in 2.08 million A-shares becoming tradable on July 18, 2025.
According to the disclosure, Innovent Biologics reported robust first-quarter 2025 financial performance, achieving revenue of 381 million yuan with net profit attributable to shareholders reaching 17.97 million yuan. This share release marks a significant milestone in the company's equity incentive program execution.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。